Company Overview
About Beta Bionics
Beta Bionics is a commercial-stage medical device company focused on transforming the management of insulin-requiring diabetes. Its flagship product is the iLet Bionic Pancreas, a device that automates insulin delivery using a proprietary adaptive algorithm that requires no carbohydrate counting, correction boluses, or manual basal rate programming from the user — the system learns from glucose readings and autonomously adjusts insulin delivery to maintain target glucose levels. The iLet is compatible with continuous glucose monitors including Dexcom G6, Dexcom G7, and FreeStyle Libre 3 Plus.
Business Model & Competitive Advantage
Beta Bionics completed its IPO on Nasdaq (ticker: BBNX) in January 2025, raising $234.6M including the full exercise of the underwriters'' overallotment option. The company reported Q1 2026 net sales of $27.6M, up 57% year-over-year, following full-year 2025 revenue growth that saw the iLet reach approximately 24,000 active users. In June 2025, Beta Bionics announced an integration agreement with Abbott to support Abbott''s future dual glucose-ketone sensor, expanding the iLet''s sensor compatibility pipeline. The company also released the Color iLet, an updated device with a full-color display for new patients.
Competitive Landscape 2025–2026
Beta Bionics'' differentiation lies in the iLet''s bionic pancreas algorithm, which is designed to be the most autonomous closed-loop system available — removing the cognitive burden of diabetes management that competing hybrid closed-loop systems still place on users. The company competes with Insulet''s Omnipod 5 and Medtronic''s MiniMed systems in the automated insulin delivery (AID) market, which is expanding as broader populations with type 1 and type 2 diabetes seek technology-assisted glucose management.
Key Differentiators
Strong Challenger
Beta Bionics is an established challenger with significant market presence and competitive offerings in Healthcare.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Doximity
Doximity is a professional network and digital health platform purpose-built for licensed physicians and other healthcare professionals in the United States. With more than two million verified clinic
Pfizer
Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The compan
Moderna
Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stép
Amgen
Amgen Inc. is one of the world's largest biotechnology companies, headquartered in Thousand Oaks, California. Founded in 1980 as Applied Molecular Genetics, Amgen pioneered the development of biologic
Veeva Systems
Veeva Systems Inc. is the leading cloud software provider for the global life sciences industry, headquartered in Pleasanton, California. Founded in 2007 by Peter Gassner (a former Salesforce executiv
Hims & Hers
Hims & Hers is a consumer telehealth and pharmacy platform founded in 2017 in San Francisco by Andrew Dudum, built on the mission of making high-quality healthcare affordable and stigma-free for condi
Compare Beta Bionics with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Beta Bionics? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Beta Bionics Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Beta Bionics vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →